Drug news
FDA approves expanded dose range for Latuda (Sunovion Pharma) in treatment of adult Schizophrenia
The FDA has approved an expanded dose range for Latuda (lurasidone), from Sunovion Pharma, for treatment of adults with Schizophrenia. The new recommended dose range (40-160 mg/day) includes approval of 120 mg/day and 160 mg/day doses plus a new 120 mg tablet. This expanded range is based on results from five studies evaluating the safety and efficacy of Latuda, in which doses of between 40 mg/day and 160 mg/day were shown to be safe and effective.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins